Evaluation of chlortetracycline-treatment timing on the duration of treatment of bovine anaplasmosis in adult cattle

金霉素治疗时机对成年牛无形体病治疗持续时间的评价

• 批准号: 10016242
• 负责人: Kathryn Elizabeth Reif
• 金额: $ 25万
• 依托单位: KANSAS STATE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-09-15 至 2024-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10016242
• 关键词: Evaluation; chlortetracycline; treatment; timing; duration

PROJECT SUMMARY This proposed project addresses FOA: NIH RFA-FD-19-024: Conduct studies to establish more targeted durations of use for certain approved antimicrobial new animal drugs in food animals. Optimizing antimicrobial usages and promoting judicious antimicrobial use are pivotal to preserving the efficacy of medically-important antimicrobials and vital to protecting food security. The long-term goal of this work is to promote sustainable livestock production through judicious antimicrobial use to control active infection of the hemoparasitic pathogen, Anaplasma marginale (Am), the etiologic agent of bovine anaplasmosis. Chlortetracycline (CTC) antimicrobials are the only FDA-approved drug to control anaplasmosis and may currently be administered continuously during the entire pasture-feeding season and beyond if under an active VFD. Continuous exposure to a single drug class for prolonged periods introduces strong selective pressure for the development of resistance. The guiding hypothesis of this proposal is that targeting antimicrobial treatment to coincide with strategic periods in the Am transmission cycle will effectively control active anaplasmosis and minimize risk of antimicrobial resistance. Through integrated cooperation between scientists and clinicians, the hypothesis will be tested, using the current FDA-approved CTC labeled dose indicated for the control of active anaplasmosis, by answering the following questions: (i) Is the current FDA- approved dosage of CTC effective to control active anaplasmosis? (ii) In what timeframe, relative to infection, must CTC treatment be initiated (targeted) to effectively control active anaplasmosis? (iii) For what duration must CTC treatment be administered to effectively control active anaplasmosis? (iv) Can a strategic interval CTC treatment protocol, derived from the above information, effectively control active anaplasmosis long-term?, and (v) Is this CTC treatment protocol broadly effective against diverse Am strains? Data generated from this proposal will provide pivotal evidence for the effectiveness of CTC, at the current FDA-approved label dose, when administered within an appropriately-timed target treatment window and for a defined treatment duration. Together, the goal of this proposal is to provide pivotal data to drug sponsors, federal policy makers, and veterinarians on an effective targeted and defined duration of use CTC treatment protocol, at the current FDA-approved label dose, to control active anaplasmosis in cattle, while also protecting antimicrobial efficacy through promoting judicious antimicrobial use.

项目摘要 本拟议项目涉及FOA：NIH RFA-FD-19-024：开展研究以确定 某些已批准的抗微生物新兽药的更有针对性的使用持续时间， 食用动物优化抗菌药物使用并促进抗菌药物的明智使用 对于保持医学上重要的抗菌剂的功效至关重要， 保障粮食安全。这项工作的长期目标是促进可持续发展。 通过明智地使用抗菌剂来控制 血液寄生病原体，边缘无浆体（Am），牛的病原体 无形体病金霉素（CTC）抗菌剂是FDA批准的唯一一种药物， 控制无形体病，目前可以在整个 牧场饲养季节及以后，如果在一个积极的VFD。持续暴露于 长期使用单一药物类别会对药物的选择性产生很大的压力， 耐药性的发展。这项建议的指导假设是， 抗菌治疗，以配合战略时期，在上午传播周期， 有效地控制活动性无形体病并最大限度地降低抗菌素耐药性风险。 通过科学家和临床医生之间的综合合作，该假设将 使用当前FDA批准的用于控制的CTC标签剂量进行测试 （一）有下列情形之一的，应当给予警告： 批准的CTC剂量是否能有效控制活动性无形体病？(ii)在什么时间段内， 相对于感染，必须启动CTC治疗（靶向）以有效控制活性 无形体病？(iii)CTC治疗必须持续多长时间才能有效 控制活动性无形体病(iv)是否可以制定策略性间隔CTC治疗方案， 从上述信息，有效地控制活动性无形体病长期？，及（v）是 这种CTC治疗方案对不同的Am菌株广泛有效？生成的数据 这一建议将为反恐委员会的有效性提供关键证据，目前 FDA批准的标签剂量，在适当的时间目标内给药 治疗窗口和规定的治疗持续时间。总之，这项提案的目标 是为药物赞助商、联邦政策制定者和兽医提供关键数据， 一个有效的有针对性的和确定的使用持续时间的CTC治疗方案，在目前 FDA批准的标签剂量，以控制牛的活动性无形体病，同时还保护 通过促进明智的抗菌药物使用来提高抗菌功效。